IONS - IONIS PHARMACEUTICALS INC

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 37.31

Open

$ 37.58

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 36.57 - $ 37.65

52 Week Range

$ 35.92 - $ 54.44

Volume

1,363,052

Average Volume

Market Cap

5.43B

Beta (5Y Monthly)

$ 0.69

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-21-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-22-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	08-04-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-24-2021	12-31-2020	10-K
15	11-04-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	03-02-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-09-2019	03-31-2019	10-Q
22	03-01-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-07-2018	03-31-2018	10-Q
26	02-28-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-09-2017	06-30-2017	10-Q
29	05-09-2017	03-31-2017	10-Q
30	03-01-2017	12-31-2016	10-K
31	11-09-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-26-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-05-2015	06-30-2015	10-Q
37	05-05-2015	03-31-2015	10-Q
38	03-02-2015	12-31-2014	10-K
39	11-07-2014	09-30-2014	10-Q
40	08-04-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-not-to-exercise-licensing-option-for-another

Tale Of Two Ionis-Partnered Neurology-Focu...
05/16/2024 16:11:55

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on k...

Ionis And Biogen Say Development Of BIIB10...
05/16/2024 11:36:34

Ionis Pharmaceuticals Announced Topline Da...
05/16/2024 11:03:18

ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe...

The Analyst Landscape: 8 Takes On Ionis Ph...
05/08/2024 18:00:33

Wells Fargo Maintains Overweight on Ionis ...
05/08/2024 14:43:58

Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target fr...

Needham Reiterates Buy on Ionis Pharmaceut...
05/08/2024 09:47:14

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

Ionis Pharmaceuticals Reports Q1 Adjusted ...
05/07/2024 11:05:13

Ionis Pharmaceuticals Q1 2024 GAAP EPS $(0...
05/07/2024 11:03:59

Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of...

Wolfe Research Upgrades Ionis Pharmaceutic...
04/10/2024 08:32:20

Wolfe Research analyst Andy Chen upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Peer Perform to Outperform.

The Latest Analyst Ratings For Ionis Pharm...
04/09/2024 15:01:18

Oppenheimer Maintains Outperform on Ionis ...
04/09/2024 12:27:41

Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...

Needham Reiterates Buy on Ionis Pharmaceut...
04/09/2024 10:34:13

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

Ionis Pharmaceuticals Announced Olezarsen ...
04/07/2024 14:08:04

– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed subst...

Ionis Pharmaceuticals To Present Olezarsen...
03/25/2024 12:20:03

– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute panc...

genetic-medicines-focused-ionis-pharmaceuticals-fatty-liver-candidate-lowers-excess-liver-fat-midstage-study-data-shows

Genetic Medicines Focused-Ionis Pharmaceut...
03/13/2024 13:52:04

Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology ...

Ionis Announces Results from Phase 2 Study...
03/13/2024 11:03:12

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 ...

Oppenheimer Maintains Outperform on Ionis ...
03/06/2024 13:57:58

Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...

Biogen Announced Interim 6-month Biomarker...
03/06/2024 12:42:43

Oppenheimer Reinstates Outperform on Ionis...
02/26/2024 13:40:35

Oppenheimer analyst Justin Kim reinstates Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target ...

Cracking The Code: Understanding Analyst R...
02/22/2024 13:00:53